Maryville, Tennessee based Molecular Pathology Laboratory Network, Inc. (MPLN) acquires the Illumina MiSeqDx™ next generation sequencing system to expand its portfolio of molecular testing and clinical research services to support growing demand in personalized medicine.

November 26 – Maryville, Tennessee – Molecular Pathology Laboratory Network, Inc. (MPLN) announced today that it has acquired the Illumina MiSeqDx™, currently the only next generation sequencing system cleared by the US Food and Drug Administration (FDA) for targeted sequencing of human genomic DNA. MPLN will be the first laboratory in the country to own the FDA cleared version of this revolutionary technology, and will leverage the system for the expansion of testing across all of its clinical laboratories including its clinical trials group Geneuity Clinical Research Services.

This exciting new technology is capable of screening numerous gene targets simultaneously at a fraction of today’s costs and does so with phenomenally high throughput. MPLN, a molecular reference laboratory specializing in Oncology, Women’s Health, and clinical research services, will utilize the Illumina MiSeqDx™ to offer physicians greater access to clinically actionable data at the gene level, and ultimately the facilitation of better patient outcomes.

“We are proud to soon host this revolutionary technology in-house and be the first lab in the country to offer such comprehensive DNA sequencing analysis,” said Dr. Roger Hubbard, MPLN Chief Executive Officer. “The Illumina MiSeqDx™ truly enhances our ability to offer the most comprehensive testing services personalized to the level of each person’s unique genetic make-up.”

About Molecular Pathology Laboratory Network, Inc.

Located in Maryville, Tennessee and with a branch laboratory in Richmond, Virginia, MPLN delivers an incomparable and unique client experience by offering the most comprehensive services and innovative technologies in laboratory medicine. Providing an expanding menu of molecular diagnostics, specialty anatomic pathology, flow cytometry, and cytogenetic testing, MPLN is dedicated to providing superior diagnostic services to their clients in pathology groups, hospitals, medical laboratories and physician groups nationwide. MPLN specializes in oncology and women’s health testing, and excels by utilizing highly qualified physicians, innovative technologies, all backed by unparalleled service to meet diagnostic challenges in a timely, cost-effective manner.